Evidence map›Paper›PMID 29444609›Full record

Observational studyJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2019

Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy.

V Damuzzo, A Russi, M Chiumente, C Masini, B Rebesco, F Gregis, S Nozza, J Pigozzo, V Chiarion-Sileni, A C Palozzo

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

V Damuzzo1 Department of Pharmaceutical and Pharmacological Sciences, School of Hospital Pharmacy, University of Padova, Padova, Veneto, Italy.ORCID https://orcid.org/0000-0002-3685-6789
A Russi1 Department of Pharmaceutical and Pharmacological Sciences, School of Hospital Pharmacy, University of Padova, Padova, Veneto, Italy.
M Chiumente2 Scientific Direction, Italian Society for Clinical Pharmacy and Therapeutics, Milano, Lombardia, Italy.
C Masini3 Pharmacy, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Emilia-Romagna, Italy.
B Rebesco4 Pharmacy, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Liguria, Italy.
F Gregis5 UOC Farmacia, UOS Galenica Clinica, Aziende Socio Sanitarie Territoriale Papa Giovanni XXIII, Bergamo, Lombardia, Italy.
S Nozza5 UOC Farmacia, UOS Galenica Clinica, Aziende Socio Sanitarie Territoriale Papa Giovanni XXIII, Bergamo, Lombardia, Italy.
J Pigozzo6 Melanoma and Esophageal Cancer Unit, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Veneto, Italy.
V Chiarion-Sileni6 Melanoma and Esophageal Cancer Unit, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Veneto, Italy.
A C Palozzo7 Pharmacy, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Veneto, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn a scenario of new expensive cancer therapies entering the market, strategies of optimisation and cost containment are crucial in oncology care. Better management of drug waste and centralization of drug preparation can be effective strategies to achieve these goals. The aim of this work is to describe the economic management of a high cost anticancer drug (ipilimumab) in some Italian reference centres.

methodsThis was an observational, multicentred study in which economical and clinical data of 21 cancer centres (418 patients) were collected during the enrollment period from February 2013 to August 2014. The follow-up period ended in July 2015.

resultsParticipants purchased 10.7% more vials of ipilimumab than necessary for compounding. The results were variable among centres, and only five centres had a deviation lower than 5% between the drug purchased and the drug prescribed. Hospitals applying the drug day reached a statistically significant residual of drug effectively used compared to the amount prescribed (P = 0.018). Consequently, the price for treating a model patient was significantly lower in those hospitals (median spare of 7456 euro per patient).

conclusionsThis study demonstrated that the careful management of drug waste and the application of drug-day, through a proper selection of vial and the ability to use the leftover drug, can generate economic savings. However, tailoring the drug stock to clinical need is still an open issue which deserves further analysis.

Indexed as

Health ResourcesInternetAntineoplastic Agents, ImmunologicalFemaleHumansIpilimumabItalyMaleMiddle AgedNeoplasmsAntineoplastic Agents, ImmunologicalIpilimumabDrug compoundingipilimumabmelanomasustainabilityvial-sharing

Identifiers

PMID29444609
PMCPMC6463268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.